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Abstract
Background: Certain drugs, for example scopolamine and timolol, show non-linear kinetic
behavior during permeation process. This non-linear kinetic behavior is due to two mechanisms;
the first mechanism being a simple dissolution producing mobile and freely diffusible molecules and
the second being an adsorption process producing non-mobile molecules that do not participate in
the diffusion process. When such a drug is applied on the skin surface, the concentration of the
drug accumulated in the skin and the amount of the drug eliminated into the blood vessel depend
on the value of a parameter, C, the donor concentration. The present paper studies the effect of
the parameter value, C, when the region of the contact of the skin with drug, is a line segment on
the skin surface. To confirm that dual-sorption process gives an explanation to non-linear kinetic
behavior, the characteristic features that are used in one-dimensional models are (1) prolongation
of half-life if the plot of flux versus time are straight lines soon after the vehicle removal, (2) the
decrease in half-life with increase in donor concentration. This paper introduces another feature
as a characteristic to confirm that dual-sorption model gives an explanation to the non-linear
kinetic behavior of the drug. This new feature is "the prolongation of half-life is not a necessary
feature if the plots of drug flux versus time is a non-linear curve, soon after the vehicle removal".
Methods: From biological point of view, a drug absorption model is said to be nonlinear if the
sorption isotherm is non-linear. When a model is non-linear the relationship between lag-time and
donor concentration is non-linear and the lag time decreases with increase in donor concentration.
A two-dimensional dual-sorption model is developed for percutaneous absorption of a drug, which
shows non-linear kinetic behavior in the permeation process. This model may be used when the
diffusion of the drug in the direction parallel to the skin surface must be examined, as well as in the
direction into the skin, examined in one-dimensional models. The dual-sorption model is an initial/
boundary value problem which consists of (1) one non-linear, two-dimensional, second-order
parabolic equation, (2) boundary conditions, (3) one initial condition. Note that, the number of
boundary conditions are, six and four, respectively, if the permeation process under consideration
is, during the application of the vehicle and during the removal of the vehicle. Adopting the
approach of method of lines, the initial/boundary value problem is transformed into an initial-value
problem, which consists of (1) a system of non-linear ordinary differential equations, (2) one initial
condition. The system of non-linear ordinary differential equations contains time-dependent non-
homogeneous terms, if the permeation process under consideration is, during the application of
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order accurate, and requires only tri-diagonal solvers, is developed.
Results: Simulation of the numerical methods described is carried out with various values of the
parameter C. The illustrations are given in the form of figures. The concentration profiles are
viewed as parabolas along the mesh lines parallel to x-axis or y-axis. The flow rates in different
subregions of the skin-region are studied. The shapes of the concentration profiles are examined
before and after the steady-state concentration is reached. The concentration reaches steady-state
when the flux reaches the steady state. The plots of flux versus time and cumulative amount of drug
eliminated into the receptor cell versus time are given.
Conclusion: Based on the various values of the parameter, C, conclusions are drawn about (1)
flow rate of the drug in different regions of the skin, (2) shape of the concentration profiles, (3) the
time required to reach the steady-state value of the concentration, (4) concentration of the drug
in different regions of the skin, when steady-state value of the concentration is reached, (5) the
time required to reach the steady-state value of the flux, (6) time required to reach the steady-
state value of the concentration of the drug, (7) half-life of the concentration of the drug and (8)
lag-time.
A comparison, between this two-dimensional model and the one-dimensional non-linear dual-
sorption model that exists in the literature, is done based on (1) the shape of the concentration 
profiles at various time levels, (2) the time required to reach the steady-state value of the 
concentration, (3) lag-time and (4) half-life.
Background
A non-linear model takes into account the property of the
skin to sorb and bind substances during the process of
permeation in addition to the ordinary dissolution. Such
a non-linear model can be used to explain the disparity
between the steady-state diffusivity of the drug in the skin
and the unsteady-state value computed from transient
(time-lag) permeation experiments, see [1]. A non-linear
dual-sorption model of percutaneous drug absorption is
described in [2]. Another mathematical model of percuta-
neous drug absorption and its exact solution is described
in [3]. In [4], the non-linear percutaneous permeation
kinetics of timolol is studied in vitro with human cadaver
skin. A model for a suspension with a finite dissolution
rate is solved numerically in [5]. All these non-linear mod-
els are one-dimensional and the region of contact of the
skin with the drug, is a single point, say x = 0, where x
measures the distance into the skin.
To the authors' knowledge, no two-dimensional non-lin-
ear mathematical model of percutaneous drug absorption
exists in the literature, where the region of contact is a line
segment, say x = 0, 0 ≤ y ≤ Lc. The purpose of this paper is
(1) to model the above situation mathematically (2) to
obtain an efficient numerical method which can use a
large time step compared to spacial discretization step;
and also handles discontinuities between initial and
boundary conditions in the mathematical model.
Methods
Model equations
(a) Concentration before the steady state is reached (Concentration 
during the application of the vehicle)
Let the drug be applied as an ointment on the skin-sur-
face, say, {(0, y) : 0 ≤ y ≤ Lc}, at time t = 0. The two-dimen-
sional model developed in [6] takes into account the drug
kinetics in the skin where the ointment is not directly
applied. The one-dimensional non-linear dual-sorption
model given in [2] postulates the total concentration of
the drug, CT, in the skin is composed of two parts, (1) the
mobile solute concentration CD, which is due to the
mechanism of simple dissolution and is expressed as CD =
KDC, in which KD is skin/receptor cell partition coefficient
and C is donor-cell concentration, (2) the immobile sol-
ute concentration CI, which is due to the adsorption proc-
ess, and is expressed as , in which
 is Langmuir's saturation constant and b is Langmuir's
affinity constant. Hence the total concentration CT, in the
skin is given by
CT = CD + CI.
Based on [6] and [2], to describe the drug kinetics at any
time t > 0, a two-dimensional non-linear dual-sorption
model is developed. Let the thickness (distance between
the skin-surface and skin-capillary boundary) of the skin
be Ls. Assuming that skin is an isotropic medium, that is,
the diffusivity κ, is the same in the x and y directions, the
C C bC bCI I D= +
* /( )1
CI
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by
where Ls, Ld, Lu and Lc are positive real numbers. Note that,
(1) is non-singular as b > 0,  > 0 and CD ≥ 0. Following
[2], the concentration along the skin-receptor cell bound-
ary may be considered to have the value zero. Assuming
that the donor-cell concentration at the uppermost epider-
mis {(0, y, t) : 0 ≤ y ≤ Lc, t > 0} is maintained at the value
C, the boundary conditions for the model are given by
CD (0, y, t) = KDC, 0 ≤ y ≤ Lc, t > 0,  (2b)
CD (Ls, y, t) = 0, -Ld ≤ y ≤ Lu, t > 0,  (2f)
Assuming that there is no drug in the skin before the
application, the initial distribution associated with the
PDE is
CD(x, y, 0) = 0,0 ≤ × ≤ Ls, -Ld ≤ y ≤ Lu  (3)
The flux J = J(t), through the skin to the receptor site, per
unit area, is given by
The cumulative amount of drug eliminated into the recep-
tor cell per unit area at time τ (see [2]) is
The initial/boundary-value problem given by (1) to (3) is
named as "problem (PA)".
(b) Concentration after the steady state is reached (Concentration 
after the vehicle removal)
Let Ts denote the time at which the steady-state is reached
by the problem (PA). Suppose that at time t = Ts, the vehi-
cle is removed instantaneously from the skin. Then (1)
remains unchanged, but the initial conditions and bound-
ary conditions changes and consequently, (2a) to (2c) dis-
appear from the mathematical model, leaving the PDE's
CD (Ls, y, t) = 0, -Ld ≤ y ≤ Lu, t > Ts  (7d)
The initial distribution associated with PDE (6) is
CD = CD (x, y, Ts), 0 ≤ x ≤ Ls, -Ld ≤ y ≤ Lu,  (8)
where CD (x, y, Ts) is computed by solving problem (PA).
The initial/ boundary-value problem given by (6) to (8) is
named as "problem (PB)".
Numerical methods
The approach to be adopted in obtaining a numerical
solution, is the method of lines in which the initial/
boundary-value problem to be solved is transformed into
a first-order initial-value problem. At any time t > 0, the
region associated with the skin is given by Rs = {(x, y) : 0 ≤
x ≤ Ls, - Ld ≤ y ≤ Lu}. The region of the contact Rc, of the
drug and the skin surface is defined as Rc = {(0, y) : 0 ≤ y ≤
Lc}. Superimpose on Rs a rectangular grid with mesh
lengths, h > 0 and H > 0, respectively, in the x and y direc-
tions. Let k > 0 be a constant time step. Let N be a positive
integer, and h = 1/(N + 1). Also it is assumed that Lc = QcH,
Lu = QuH, Ld = QdH, where Qc, Qu and Qd are positive inte-
gers. The grid points are given by (xl, ym, tj); xl = lh, l =
0(1)(N + 1), ym = mH, m = -Qd(1)Qu and tj= jk, j = 0, 1, 2,
...s, ...etc. with sk = Ts. The values tj represent the time-levels
for the problems (PA) and (PB) for j ≤ s and j ≥ s respec-
tively. The finite-difference solution which approximates
the solution CD (x, y, t) of the two-dimensional parabolic
equation (1), is sought at each mesh point (xl, ym, tj) in the
region [Rs- Rc - {(Ls, y), -Ld ≤ y ≤ Lu}] × t > 0. Note that, for
∂
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the problem (PA), the differential equation (1), subject to
the boundary conditions (2a) to (2f), is discretized at all
grid points in the region [Rs - Rc -{(Ls, y), -Ld ≤ y ≤ Lu}] × [0
≤ t ≤ Ts]. For the problem (PB), the differential equation
(6), subject to the boundary conditions (7a) to (7d), is
discretized at all grid points in the region [Rs -{(Ls, y), -Ld
≤ y ≤ Lu}] × [t > Ts]. For notational simplicity, denote
Discretization for problem (PA)
At any time-level t = tj,  or , the {(Qd + Qu + 1)
(N + 1) - (Qc + 1)} elements will be ordered in rows par-
allel to the x-axis and in vector form, and will be denoted
by CD(t) and Q(t), where Q(t) is due to the boundary con-
dition (2b). For W = CD and Q, and  =  or ,
denote
In the above notation n takes the value 0 if m ≠ 0(1)Qc and
takes the value 1 otherwise. The vector CD(t) is a vector of
unknowns and the vector Q(t) is given by
All other  are zero. In the following discretizations,
(xl, ym), pl,m, ql,m and CDl,m, respectively, denote (xl, ym, tj),
,  and . At any time-level t = tj, the differen-
tial equation (1) can be discretized as
If  and  are respectively, suitable
approximations to CDxx;l;m and CDyy;l;m, the above discreti-
zation can be written as
At an interior grid point (xl, ym),  and 
are given by
If (xl, ym) is a boundary point, using the boundary condi-
tions (2a) to (2f),  and  are given by
where
A1 = 0, B1 = 2, if l = 0, m = -Qd(1)(-1), (Qc + 1)(1)Qu,
A1 = 0, B1 = 1, if l = 1, m = 0(1)Qc,
A1 = 1, B1 = 1, if l = 1(1)N - 1, m = -Qd(1)Qu,
A1 = 1, B1 = 0, if l = N, m = -Qd(1)Qu,
A2 = 0, B2 = 2, if l = 0(1)N, m = -Qd,
A2 = 2, B2 = 0, if l = 0(1)N, m = Qu,
A2 = 1, B2 = 1, if l = 0, m = (-Qd + 1)(1)(-2), (Qc + 2)(1)(Qu
- 1),
A2 = 1, B2 = 0, if l = 0, m = -1
A2 = 0, B2 = 1, if l = 0, m = (Qc + 1).
System of ordinary differential equations
Combining the discretizations (9) together with expres-
sions for  and  given by (10) and (11)
respectively, a system of ordinary differential equations is
formed as
where
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Qc + 1. The abbreviations m1, m2, ... etc. represent m + 1,
m + 2, ... etc. For m ≠ 0, 1, 2, ...Qc, Em and Fm are square
matrices of order N + 1 and are given by
For m = 0, 1, 2, ..., Qc, Em and Fm are square matrices of
order N and are given by
For the values of m = -1, Qc + 1, and m = 0, Qc, the matrices
Gm are of orders (N + 1) × N and N × (N + 1), respectively,
and are given by
For the values of m = 0, 1, ..., Qc, m ≠ 0, 1, 2, ...Qc, the
matrices Om are the zero matrices of orders N and N + 1
respectively. The matrices Od and Oc are zero matrices of
orders (N + 1) × N and N × (N + 1), respectively.
Recurrence relation and its implementation via sequential algorithm
In [7], an eight stage sequential algorithm is described to
solve two space linear parabolic equations. In [2], a
sequential algorithm of two tridiagonal solvers is
described to solve one-space non-linear dual-sorption
model. To the author's knowledge, there is no sequential
algorithm in the literature to solve the two-dimensional
non-linear parabolic equation (1). The aim of this section
is to develop an eight-stage sequential algorithm of tridi-
agonal solvers, to solve the system of non-linear ordinary
differential equations given by (12), which gives the solu-
tion of two-space non-linear parabolic equation (1). The
main idea used is, to rewrite the system of equations (12)
in such a way that, the numerical techniques described in
[7] and [2] can be extended to two-space non-linear equa-
tions. To achieve this, we proceed as follows.
Let Q(t) = R(t) + S(t), where the elements of the vectors
R(t) and S(t) are, respectively, denoted by  and ,
and are defined by
Note that the vector, R(t), is the contribution of CDxx to the
vector Q(t). The vector, S(t), is the contribution of CDyy to
the vector Q(t). The system of non-linear ordinary differ-
ential equations given by (12) can be written as
It is known (see [2,8]) that the system of ordinary differ-
ential equations given by (12), subject to the initial con-
dition (3), satisfies the recurrence relation
where D* = diag{d/dt}. The exponential term in the recur-
rence relation (16) will be approximated by its (2, 0) Padé
approximant to give
which, following pre-multiplication, gives
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four-stage sequential algorithm is developed to obtain
, which is an approximation to CD(t + k) in (17). It is
given by
(I - r1kE) Z = CD(t) + r1kR(t),  (18a)
(I - r2kE) V = Z + r2kR(t),  (18b)
(I - r1kF) Z = V + r1kS(t),  (18c)
(I - r2kF)  (t + k) = Z + r2kS (t).  (18d)
where  (see [8])
Another solution, , which is an approximation to CD(t
+ k) in (17), is obtained by interchanging the matrices E
and F; and the vectors R and S; in (18a) to (18d). It is
given by
(I - r1kF) Z = CD(t) + r1kS(t),  (18e)
(I - r2kF) V = Z + r2kS(t),  (18f)
(I - r1kE) Z = V + r1kR(t),  (18g)
(I - r2kE)  (t + k) = Z+ r2kR (t).  (18h)
Note that the approximations,  and , given by
(18d) and (18h), are first-order accurate in time and their
linear combination defined by
is second order accurate in time. The eight-stage algo-
rithm, defined by (18a) to (18i) is, L0 stable and uses only
tridiagonal solver.
Initial/boundary value problem (PB)
The "problem (PB)" is modelled by the equations (6) to
(8). At any time-level t = tj, j ≥ s, , the (Qd + Qu + 1)
× (N + 1) elements, will be ordered in rows parallel to the
x-axis and in vector form, and will be denoted as CD(t),
with
At a grid point xl, ym, the required discretization is
For l ≠ 0, m ≠ (-Qd + 1) (1) (Qu - 1);  and 
are given by (10) and for l = 0, m = (-Qd + 1)(1)(Qu - 1),
 and
Combining the discretizations given by (19), a system of
differential equations is formed as
in which
In the above matrices, the value of m is -Qd and m1 = m +
1, m2 = m + 2,... The matrices Ei and Fi, i = -Qd(1)Qu, are
square matrices of order N +1, and are given by (13). Pro-
ceeding as in problem (PA), the eight-stage algorithm to
solve the system of differential equations (20), subject to
the initial conditions (8), is
(I - r1kE) Z = CD(t),  (21a)
(I - r2kE) V = Z ,  (21b)
(I - r1kF) Z = V,  (21c)
(I - r2kF)  (t + k) = Z,  (21d)
(I - r1kF) Z = CD(t),  (21e)
(I - r2kF) V = Z,  (21f)
(I - r1kE) Z = V,  (21g)
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BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/40(I - r2kE)  (t + k) = Z,  (21h)
Note that the sequential algorithm defined by (21a) to
(21i) is obtained from the equations (18a) to (18i),
replacing the vectors R(t) and S(t), by the zero vector of
length (Qd + Qu+ 1) × (N + 1). This shows the efficiency of
the splitting of the vector Q(t), and the eight-stage algo-
rithm developed in problem (PA).
Stability Analysis
The stability analysis of two-stage sequential algorithm for
the solution of one-space non-linear second-order para-
bolic equation is described in [2]. The stability analysis of
four-stage sequential algorithm for the solution of two-
space second-order parabolic equation is described in [7].
In this section, following [7] and [2], it is to prove that the
eight-stage sequential algorithms described by (18a) to
(18i) and (21a) to (21i) are L0 stable.
The amplification matrix R*(k(E + F)) of the method
defined by (18a) to (18d) is given by
neglecting the higher order terms O (-k3).
Hence the symbol R*(-z), of the method defined by (18a)
to (18d), to evaluate  (t + k) is given by
Similarly the symbol R+(--z), of the method defined by
(18e) to (18h), to evaluate (t + k) is given by
In (22) and (23), z = -kλ where λ is an eigen value of the
matrix E + F. Hence using (22) and (23) the symbol, S(-z),
of the method (18i) is
The method is L0 stable if
| S(-z) | ≤ 1  (24)
S(-z) → 0, as z → ∞
• Proof of (24):- Applying Brauer's theorem, it can be
shown that all the eigen values λ of the matrix E + F are
negative. Hence, z = kλ > 0.
• Proof of (25):-
From (24) and (25), it is concluded that the numerical
method defined by (18a) to (18i) is L0 stable. Similarly
the numerical method defined by (21a) to (21i) is L0 sta-
ble. Since the method is L0 stable, the discontinuities
around y = 0 and y = Lc are not propagated.
Results and discussion
In order to examine the behavior of the recurrence rela-
tions (18a) to (18i) and (21a) to (21i), a series of five
numerical experiments, similar to those described in [2],
are carried out for two space dimensions. In these experi-
ments the parameter-values used are those used in [2]. For
the experiments numbered n = 1, 2, 3, 4, and 5, the param-
eter C was given the values 4.1, 19.5, 43.1, 51.4 and 64.0
respectively. The rest of the parameter values are given by
Ls = 0.004 cm, Ld = 0.0320 cm, Lc = 0.128 cm, Lu = 0.160 cm,
k = 0.1 h, H = 0.0004, κ = 0.0000018 cm2/h,  = 5.0 mg/
ml, KD = 1.1, h = 0.0002, N = 19, Qc = 320, Qu = 400, Qd =
80, b = 0.5599 ml/mg.
It was assumed in all numerical experiments that the drug
was applied until steady-state concentration profile is
reached. Let  denotes the time in hours, at which the
concentration profiles for the nth (n = 1, 2, 3, 4 and 5)
experiment reaches the steady-state. Suppose that at time
t = , the vehicle is removed instantaneously from the
skin. The pattern of the concentration profile is observed
for fifty hours more, after the vehicle is removed at the
steady-state. For the nth (n = 1(1)5) experiment, the values
of CD are computed (1) using the sequential algorithm
(18a) to (18i), in the time interval 0 <t ≤ , (2) using
the sequential algorithm (21a) to (21i), in the time inter-
val  <t ≤  + 50. Following [2], for the value of n =
1 (C = 4.4), the profiles of concentration CD at t = 0.5. 1.0,
2.0, 3.0, 4.5 and 6.0 are given in figure 1. In figure 2, the
profiles of concentration CD are given at t = 24.0, 26.0,
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BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/4028.0, 30.0, 32.0 and 34.0. In figure 3 the profile of con-
centration CD, are given at time t =  = 128.7, the time
at which concentration, CD, reaches the steady state for the
first experiment. In figures 1, 2 and 3, the concentration
profiles are viewed as parabolas along mesh lines x = xl, l
= 0(1) N. The figures 1 and 2 show the flow rate in differ-
ent subregions of the skin region Rs, before the concentra-
tion reaches the steady state. Figure 3 shows the shape of
the concentration profile when the concentration reaches
steady-state.
In figure 4 and figure 5, for the value of C = 4.4, the con-
centration profiles at t = 0.5 and 3.0 are viewed as parab-
olas along the mesh lines y = ym, m = -Qd(1)Qu. Figure 4
and figure 5 show the change in shape of the parabolas in
the region away from the region of contact of drug and
skin. In figure 6, corresponding to the value of C = 4.4, the
concentration profiles at t =  = 128.7 are shown along
the mesh lines y = ym, m = Qc(1)Qu. The figure 6 shows the
importance of two-dimensional modelling.
Corresponding to each value of n = 1(1)5, the concentra-
tion profiles at t =  are given in figures 7, 8, 9, 10 and
11, respectively. The above figures show the effect of the
value of C on the steady-state concentration CD in differ-
ent regions of Rs.
In figure 12, the concentration profiles for the value of C
= 4.4 are given at t = 128.7, 130.7, 132.7, 134.7, 136.7,
and 138.7. This graph show the rate of decreasing of the
Concentration profiles for C = 4.4, viewed as parabolas along mesh lines x = xl, l = 0(1)N; t = 0.5, 1.0, 2.0, 3.0, 4.5, 6.0Figure 1
Concentration profiles for C = 4.4, viewed as parabolas along mesh lines x = xl, l = 0(1)N; t = 0.5, 1.0, 2.0, 3.0, 4.5, 6.0.
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BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/40concentration in different regions of Rs after the removal
of the vehicle.
The Ae versus time and J versus time profiles are monitored
for the time interval 0 ≤ t ≤  + 50 in each experiment.
The values J and Ae are computed at each time step using
the trape-zoidal rule to approximate the integrals in (4)
and (5). Thus, to second-order accuracy, for j = 1, 2, 3,...
etc,
where
and
In literature see [2], the drug absorption experiments are
monitored for a large time interval. Hence it is desirable
to use a numerical method which gives acceptable results
with larger time steps compared to spacial discretization.
Since the numerical method used in this section are L0 sta-
ble, it is expected to give accurate results when a large time
Concentration profiles for C = 4.4, viewed as parabolas along mesh lines x = xl, l = 0(1)N; t = 24.0, 26.0, 28.0, 30.0, 32.0, 34.0Figure 2
Concentration profiles for C = 4.4, viewed as parabolas along mesh lines x = xl, l = 0(1)N; t = 24.0, 26.0, 28.0, 30.0, 32.0, 34.0.
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BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/40step is used. Note that the conclusions obtained from all
the five experiments are independent of the time step k. As
an illustration, with k = 0.1 and k = 0.01, J versus time pro-
files are monitored for the first experiment (C = 4.4) and
are given in figure 15. The time required to reach the
steady-state value of the flux with k = 0.1 and k = 0.01
respectively are t = 128.7 and t = 130.37. When the numer-
ical computation is done with k = 0.01, the difference in
flux during the time interval [128.7 130.37] is 10-10,
which is negligible. It is also noted that even if the drug is
Concentration profiles for C = 4.4, viewed as parabolas along mesh lines at x = xl,  = 0(1)N; t = 128.7Figure 3
Concentration profiles for C = 4.4, viewed as parabolas along 
mesh lines at x = xl, l = 0(1)N; t = 128.7.
Concentration profiles for C = 4.4, viewed as parabolas along mesh lines at y = ym, m = -Qd(1)Qu; t = 0.5Figure 4
Concentration profiles for C = 4.4, viewed as parabolas along 
mesh lines at y = ym, m = -Qd(1)Qu; t = 0.5.
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Concentration profiles for C = 4.4, viewed as parabolas along mesh lines at y = ym, m = -Qd(1)Qu; t = 3.0Figure 5
Concentration profiles for C = 4.4, viewed as parabolas along 
mesh lines at y = ym, m = -Qd(1)Qu; t = 3.0.
Concentration profiles for C = 4.4, viewed as parabolas along mesh lines at y = ym, m = 0(1)Qc; t = 128.7Figure 6
Concentration profiles for C = 4.4, viewed as parabolas along 
mesh lines at y = ym, m = 0(1)Qc; t = 128.7.
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BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/40removed at t = 130.37 instead of t = 128.7, the conclusions
drawn in next section remain valid.
Conclusion
Conclusion is presented in five parts.
Part 1:- Conclusions based on concentration profiles till 
steady-state concentration, CD, is reached
Concentration profiles at various time levels are examined
until steady state is reached. Graphically these
concentration profiles are represented as parabolas along
mesh lines x = xl, l = 0(1) N or parabolas along mesh lines
Concentration profiles for C = 4.4, when steady-state is reach dFigure 7
Concentration profiles for C = 4.4, when steady-state is 
reached.
Concentration profiles for C = 19.5, when steady-state is reach dFigure 8
Concentration profiles for C = 19.5, when steady-state is 
reached.
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Concentration profiles for C = 43.1, when steady-state is reach dFigure 9
Concentration profiles for C = 43.1, when steady-state is 
reached.
Concentration profiles for C = 51.4, when steady-state is reach dFigure 10
Concentration profiles for C = 51.4, when steady-state is 
reached.
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BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/40y = ym, m = -Qd(1)Qu. Divide the region of skin, Rs, into two
mutually exclusive regions R1 and R2 as follows.
R1 = Rc × Ls and R2 = Rs - R1.
The following conclusions are drawn based on drug kinet-
ics in the regions R1, R2 and Rs.
(1) In figure 1 the concentration profiles are viewed as
parabolas along mesh lines x = xl, l = 0(1)N. Consider the
flow rate of concentration of the drug in the region R1.
From the subplots (a) to (c) of figure 1, it is concluded
that during the initial time levels, flow rate towards the
skin surface is larger than flow rate towards the skin-cap-
illary boundary. Later-on time levels (from subplots (c) to
(f) of figure 1), flow rate towards the skin-capillary
boundary becomes larger than flow rate near to the skin
surface.
(2) In figure 2 the concentration profiles are viewed as
parabolas along mesh
lines x = xl, l = 0(1)N.
From figure 1 and figure 2 it is concluded that in the
region R2, the flow rate near to the skin surface is larger
than flow rate towards the skin-capillary boundary.
(3) Consider the flow rate in the whole region Rs. From
figure 1 and figure 2 it is concluded that, during the initial
time levels, flow rate in the region R1 is larger than the
flow rate in the region R2. But later-on time levels, flow
rate in the region R2 becomes larger than the flow rate in
the region R1, leading to a steady-state concentration pro-
file as given in figure 3. In figure 3 the concentration pro-
files are viewed as parabolas along mesh lines x = xl, l =
0(1)N.
(4) At any time level t = tj, consider the concentration of
the drug along the mesh line x = xl, l = 0(1)N. From figure
1, 2 and 3, it is concluded that the concentration of the
drug at a mesh point (xl, ym, tj) ∈ R1, m = 0(1)Qc is larger
than the concentration of the drug at a mesh point (xl, ym,
tj) ∈ R2, m ≠ 0(1)Qc.
(5) In figure 4 and figure 5, the concentration profiles are
viewed as parabolas along mesh lines y = ym, m = -
Qd(1)Qu. From figure 4 it is concluded that, during the ini-
tial time-levels, the shape of the parabolas in the whole
region Rs retains the same shape as the shape of the con-
centration profiles given in page 97 of [2]. If a one-dimen-
sional model of drug absorption was sufficient, the
following results are expected from [2].
• When steady-state concentration reaches, the shape of
the concentration profiles viewed along the mesh lines y =
ym, m = -Qd(1)Qu is same as the shape of the parabolas
given in page 97 of [2].
• When steady-state concentration reaches, concentration
profiles along the mesh lines y = ym, m = 0(1)Qc are straight
lines.
Contrary to this result, the following results are obtained
from two-dimensional modelling.
5.1 From figure 4 and figure 5 it is concluded that, as time
increases, the parabolas in the region R2 have a convex
shape, whereas the parabolas given in page 97 of [2] have
a concave shape.
5.2 The concentration profiles along the mesh lines, y =
ym, m = 5(1) Qc - 5 are straight lines. These straight lines are
shown in figure 6.
5.3 The concentration profiles along the mesh lines, y =
ym, m = 0, 1, 2, 3, 4, Qc - 4, Qc - 3, Qc - 2, Qc - 1 and Qc are
not straight lines, but they have the shape as shown in fig-
ure 6.
Even though the illustration of figures is done only for
one experiment (with n = 1, C = 4.4), that is only for the
first experiment, the conclusions drawn are true for all
other experiments (that is, for all values of C).
Concentration profiles for C = 64.0, when steady-state is reach dFigure 11
Concentration profiles for C = 64.0, when steady-state is 
reached.
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BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/40Part 2:-Conclusions based on concentration profiles when 
steady-state value of concentration is reached
The steady-state concentration profiles for all the five
experiments are given in figure 7, figure 8, figure 9, figure
10 and figure 11. From these steady-state concentration
profiles, the following conclusions are drawn.
(1) As the value of C increases, the concentration at any
point (xl, ym, tj) increases.
(2) As the value of C increases, the difference between the
concentrations of the drug at mesh points (xl, ym, tj) ∈ R1,
m = 0(1)Qc and (xl, ym, tj) ∈ R2, m ≠ 0(1)Qc increases.
(3) As the value of C increases, the difference between the
concentrations of the drug at mesh points (x0, ym, tj) and
(xN-1, ym, tj) increases for m = -Qd(1)Qc. This increase in dif-
ference is more prominent in the region R1 than in the
region R2.
Part 3:-Conclusions based on concentration profiles after 
the removal of the vehicle when steady-state is reached
The vehicle is removed when the concentration reaches
steady-state. The concentration profiles are examined for
ten more hours, after the vehicle-removal, in an interval of
two hours. In figure 12, these concentration profiles are
given for n = 1 (C = 4.4), at time levels t =  = 128.7, t =
130.7, t = 132.7, t = 134.7, t = 136.7, and 138.7. From fig-
ure 12 the following conclusions are made.
Concentration profiles for C = 4.4 viewed as parabolas along mesh lines x = xl, l = 0(1)N; t = 128.7, 130.7, 132.7, 134.7, 136.7, 138.7Figure 12
Concentration profiles for C = 4.4 viewed as parabolas along mesh lines x = xl, l = 0(1)N; t = 128.7, 130.7, 132.7, 134.7, 136.7, 
138.7.
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BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/40(1) After the removal of the vehicle, rate of decrease in the
region R1 is larger than that in R2.
(2) After the removal of the vehicle, rate of decrease near
to the region of skin-surface is larger than that near to
region of skin-capillary boundary. Even though the illus-
tration of figures is done only for one experiment (with n
= 1, C = 4.4), that is only for the first experiment, the con-
clusions drawn are true for all other experiments also.
Part 4:-Conclusions based on figure 13 (flux versus time) 
and figure 14 (Ae versus time)
The graphs of J versus time and Ae versus time for the time
interval 0 ≤ t ≤ (  + 50) are shown in figure 13. The fol-
lowing conclusions are drawn based on figure 13.
(1) As the value of C increases, the steady-state value of
flux increases.
(2) As the value of C increases half-life decreases, during
the time levels, soon after the vehicle-removal. There is no
prolongation of half-life during later-on time, as stated in
[2]. It is evident from figure 13 that, the plots of a drug
flux versus time is a non-linear curve, soon after the vehicle
removal. Hence, in experimental studies even when the
prolongation of half-life is not seen, the nonlinearity of
drug flux versus time can be introduced as a characteristic
to confirm that dual-sorption model gives an explanation
to non-linear kinetic behavior of the drug.
The graphs of Ae versus time for the time interval 0 ≤ t ≤
 + 50 are shown in figure 14.
J versus time profiles for various values of CFigure 13
J versus time profiles for various values of C.
Ae versus time profiles for various values of CFigu e 14
Ae versus time profiles for various values of C.
0 20 40 60 80 100 120 140 160
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
n=1, C=4.4, T(1)
s
=128.70
n=2, C=19.5, T(2)
s
=104.10
n=3, C=43.1, T(3)
s
=105.70
n=4, C=51.4, T(4)
s
=125.30
n=5, C=64.0, T(5)
s
=115.60
 time
 
J
0 5 10 15 20 25 30
0
20
40
60
80
100
 time
 
Ae
C=4.4
C=19.5
C=43.1
C=51.4
C=64.0
J versus time profiles for C = 4.4 with k = 0.1 and k = 0.01Figure 15
J versus time profiles for C = 4.4 with k = 0.1 and k = 0.01.
: 
C 4.4 19.5 43.1 51.4 64.0
TL1 3.44 2.29 1.99 1.93 1.84
TL2 3.67 2.52 2.16 2.11 2.04
0 20 40 60 80 100 120 140 160 180
0
0.05
0.1
0.15
0.2
0.25
 time
 
J
K=0.1
K=0.01
Ts
n( )
Ts
n( )Page 14 of 15
(page number not for citation purposes)
BioMedical Engineering OnLine 2005, 4:40 http://www.biomedical-engineering-online.com/content/4/1/40Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
(3) As the value of C increases, at any time level t = tj, the
value of Ae(t) increases.
(4) As the value of C increases, lag-time decreases. The lag-
time is computed as t-intercepts of the linear portion of
graphs of Ae versus time. For various values of C, the lag-
times are compared with the lag-times given in [2]. Let TL1
denotes the lag-times quoted in [2] as a result of one-
dimensional modelling of drug-absorption and TL2
denotes the lag-times obtained as a result of two-dimen-
sional modelling. Table 1 gives the values of TL1 and TL2,
corresponding to each value of C.
From Table 1 it is concluded that, for a particular value of
C, the lag-time obtained as a result of two-dimensional
modelling is greater than the lag-time obtained as a result
of one-dimensional modelling. For a linear model, lag
time is independent of donor concentration C. The linear
model corresponding to (1) is obtained by substituting
 = 0. Its lag time is computed as 1.56 which is greater
than 1.44, the lag-time obtained from the one-dimen-
sional linear model (substitute  = 0 in (8) of [2]).
It is an established fact that the drug permeation profiles
of a nonlinear model is different from that of a linear
model, as a non-linear model assumes that the drug
molecules are either dissolved or immobile inside the
skin. In this article it is shown that the drug permeation
described by the two-dimensional non-linear model is
different from one-dimensional non-linear model, as the
two-dimensional model takes into account the drug
kinetics at the site distant from the area where the oint-
ment is directly applied.
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